SARS Coronavirus Nucleoprotein

Size

£659.00

SKU:: 544067
Purity:: Purified by Protein A affinity chromatography or sequential differential precipitations.
Storage Conditions:: -20°C
Supplier:: United States Biological
Host:: Mouse
Clone:: 3864
Format:: Supplied as a liquid in 0.01M PBS, pH 7.2, 0.09% sodium azide.
Extra Details:: Severe acute respiratory syndrome (SARS) is a lower respiratory tract illness that was first reported in patients from the Guandong Province of China in November 2002. The causative agent, which was previously unknown, was isolated in 2003 and named as SARS coronavirus (SARS-CoV). The SARS coronavirus is an enveloped, single-stranded, positive RNA virus of the family Coronoviridae (NCBI) The virus is thought to have a zoonotic origin, with the horseshoe bat being the primary natural reservoir, but this has not been confirmed. Mammals, including the palm civet, may act as intermediate hosts. The coronavirus nucleocapsid protein is the major structural component of virions that associates with genomic RNA to form a long, flexible, helical nucleocapsid. Sequence comparison of the N genes of five strains of the coronavirus mouse hepatitis virus suggests a three-domain structure for the nucleocapsid protein. Anti-SARS-CoV Nucleocapsid (N). In 2003, the SARS coronavirus spread rapidly and affected over 8,000 people in 26 countries. The rapid spread of SARS-CoV is thought to be due to person-to-person transmission of the virus via aerosol droplets or close contact with infected individuals. Since the end of the SARS epidemic, cases of SARS have only occurred in laboratory workers that have been accidently infected (WHO). The symptoms of SARS infection are like influenza and include fever, malaise, muscle pain, headache, diarrhoea and shivering. Clinical symptoms may also include coughing and shortness of breath. Respiratory distress may rapidly develop in some patients, resulting in death. SARS disease has a high rate of mortality and resulted in 774 deaths during the first epidemic in 2003. Currently, no licenced vaccine is available for the prevention of SARS infection. SARS continues to be of global health concern due to the rapid spread of the virus, the high mortality rate and the fears of a future SARS outbreak. Applications: Suitable for use in Immunofluorescence and ELISA. Other applications not tested. Recommended Dilution: Immunofluorescence (SARS-CoV): 1:10-1:50 ELISA (SARS-CoV and SARS-CoV-2): 1:20-1:200 Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Shipping Conditions:: Blue Ice